Esperion Therapeutics (ESPR) Operating Margin (2019 - 2025)
Historic Operating Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 11.41%.
- Esperion Therapeutics' Operating Margin rose 196300.0% to 11.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.67%, marking a year-over-year decrease of 152400.0%. This contributed to the annual value of 16.37% for FY2024, which is 1500900.0% up from last year.
- Esperion Therapeutics' Operating Margin amounted to 11.41% in Q3 2025, which was up 196300.0% from 8.61% recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Operating Margin registered a high of 52.47% during Q1 2024, and its lowest value of 1038.15% during Q1 2021.
- In the last 5 years, Esperion Therapeutics' Operating Margin had a median value of 131.37% in 2023 and averaged 178.52%.
- Per our database at Business Quant, Esperion Therapeutics' Operating Margin soared by 30078200bps in 2021 and then crashed by -1979800bps in 2022.
- Esperion Therapeutics' Operating Margin (Quarter) stood at 361.2% in 2021, then soared by 37bps to 225.92% in 2022, then surged by 42bps to 131.37% in 2023, then skyrocketed by 95bps to 6.4% in 2024, then plummeted by -78bps to 11.41% in 2025.
- Its Operating Margin stands at 11.41% for Q3 2025, versus 8.61% for Q2 2025 and 34.0% for Q1 2025.